By Rishika Sadam
MUMBAI (Reuters) -Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world’s most populous nation, a senior executive said on Thursday.
“I do think there is promise for products like that (orforpligron) in India, if it does get approved,” Winselow Tucker, Lilly India’s president said at an event in Mumbai.
Tucker, however, did not indicate when Lilly plans to launch the drug.
The drugmaker has bid for approval for the experimental pill after latest clinical data showed it lowered average blood sugar and weight in a head-to-head trial of adults with type-2 diabetes more effectively than rival Novo Nordisk’s older GLP-1 pill Rybelsus.
Lilly’s orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company’s blockbuster injection tirzepatide, sold under the brand names Mounjaro and Zepbound.
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Sonia Cheema)
Comments